Profile
Nanovista is developing novel, multi-modality imaging agents for oncology. Nanovista is enabling surgical oncologists with tools to visualize tumours in real-time during surgery with the goal of improving cancer surgery outcomes. The CF800 liposomal imaging agent accumulates specifically at the tumour boundary with healthy tissue and enables the precise visualization of multiple solid tumour types using existing operating room equipment with CT and near-infrared spectrum imaging capabilities.
Event details
Date: September 21 - 23, 2022
Event contact
Patricia Cosgrove
Area Director
USA: Life Sciences
Tel: +1 647-293-6306
Email: patricia.cosgrove@ontario.ca
Participants
10 in total
-
Able Innovations is solving the repetitive and labour-intensive task of patient transfers by developing robotic medical… -
Cohesys is a Toronto-based medical device manufacturer that has developed BoneTape, a resorbable tape for bone fracture… -
EmergConnect aims to change the way patients think about same-day care through a digital platform for patient self-… -
Hyivy Health was created after founder Rachel Bartholomew’s recent fight with cervical cancer. She wanted to change the… -
Nanovista is developing novel, multi-modality imaging agents for oncology. Nanovista is enabling surgical oncologists… -
ProteinQure has built the best computational platform for designing small exotic protein therapeutics. ProteinQure… -
QuadroCore is pushing the limits within the field of Mass Spectrometer (MS) technology. The company is… -
QurCan therapeutics is a biotech company developing next-generation chemo and gene therapies using its proprietary… -
Quthero is an early-stage life sciences startup developing applications for its platform technology--a unique, patented… -
Translucent Computing’s Emrchiver enables value-based care for better patient outcomes without vendor lock-in.…